Cargando…

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Canzoni, Marco, Marignani, Massimo, Sorgi, Maria Laura, Begini, Paola, Biondo, Michela Ileen, Caporuscio, Sara, Colonna, Vincenzo, Casa, Francesca Della, Conigliaro, Paola, Marrese, Cinzia, Celletti, Eleonora, Modesto, Irene, Peragallo, Mario Stefano, Laganà, Bruno, Picchianti-Diamanti, Andrea, Rosa, Roberta Di, Ferlito, Claudia, Salemi, Simonetta, D’Amelio, Raffaele, Stroffolini, Tommaso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696870/
https://www.ncbi.nlm.nih.gov/pubmed/33207663
http://dx.doi.org/10.3390/microorganisms8111792
_version_ 1783615503152971776
author Canzoni, Marco
Marignani, Massimo
Sorgi, Maria Laura
Begini, Paola
Biondo, Michela Ileen
Caporuscio, Sara
Colonna, Vincenzo
Casa, Francesca Della
Conigliaro, Paola
Marrese, Cinzia
Celletti, Eleonora
Modesto, Irene
Peragallo, Mario Stefano
Laganà, Bruno
Picchianti-Diamanti, Andrea
Rosa, Roberta Di
Ferlito, Claudia
Salemi, Simonetta
D’Amelio, Raffaele
Stroffolini, Tommaso
author_facet Canzoni, Marco
Marignani, Massimo
Sorgi, Maria Laura
Begini, Paola
Biondo, Michela Ileen
Caporuscio, Sara
Colonna, Vincenzo
Casa, Francesca Della
Conigliaro, Paola
Marrese, Cinzia
Celletti, Eleonora
Modesto, Irene
Peragallo, Mario Stefano
Laganà, Bruno
Picchianti-Diamanti, Andrea
Rosa, Roberta Di
Ferlito, Claudia
Salemi, Simonetta
D’Amelio, Raffaele
Stroffolini, Tommaso
author_sort Canzoni, Marco
collection PubMed
description Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Disease diagnostic groups in Italy. The study enrolled 302 subjects, sex ratio (M/F) 0.6, mean age ± standard deviation 57 ± 15 years, 167 (55%) of whom were candidates for immunosuppressive therapy. The Spondyloarthritis group included 146 subjects, Chronic Arthritis 75 and Connective Tissue Disease 83 (two patients had two rheumatic diseases; thus, the sum is 304 instead of 302). Ten subjects (3%) reported previous anti-HBV vaccination and tested positive for anti-HBs alone with a titer still protective (>10 IU/mL). Among the remaining 292 subjects, the prevalence of positivity for HBsAg, isolated anti-HBc, anti-HBc/anti-HBs, and any HBV marker was 2%, 4%, 18%, and 24%, respectively. A total of 26/302 (9%) patients with γ-globulin levels ≤0.7 g/dL were more frequently (p = 0.03455) prescribed immunosuppressive therapy, suggesting a more severe rheumatic disease. A not negligible percentage of rheumatic patients in Italy are at potential risk of HBV reactivation related to immunosuppressive therapy. Before starting treatment, subjects should be tested for HBV markers. Those resulting positive should receive treatment or prophylaxis with Nucleos (t) ides analogue (NUCs) at high barrier of resistance, or pre-emptive therapy, according to the pattern of positive markers. HB vaccination is recommended for those who were never exposed to the virus.
format Online
Article
Text
id pubmed-7696870
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76968702020-11-29 Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy Canzoni, Marco Marignani, Massimo Sorgi, Maria Laura Begini, Paola Biondo, Michela Ileen Caporuscio, Sara Colonna, Vincenzo Casa, Francesca Della Conigliaro, Paola Marrese, Cinzia Celletti, Eleonora Modesto, Irene Peragallo, Mario Stefano Laganà, Bruno Picchianti-Diamanti, Andrea Rosa, Roberta Di Ferlito, Claudia Salemi, Simonetta D’Amelio, Raffaele Stroffolini, Tommaso Microorganisms Article Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Disease diagnostic groups in Italy. The study enrolled 302 subjects, sex ratio (M/F) 0.6, mean age ± standard deviation 57 ± 15 years, 167 (55%) of whom were candidates for immunosuppressive therapy. The Spondyloarthritis group included 146 subjects, Chronic Arthritis 75 and Connective Tissue Disease 83 (two patients had two rheumatic diseases; thus, the sum is 304 instead of 302). Ten subjects (3%) reported previous anti-HBV vaccination and tested positive for anti-HBs alone with a titer still protective (>10 IU/mL). Among the remaining 292 subjects, the prevalence of positivity for HBsAg, isolated anti-HBc, anti-HBc/anti-HBs, and any HBV marker was 2%, 4%, 18%, and 24%, respectively. A total of 26/302 (9%) patients with γ-globulin levels ≤0.7 g/dL were more frequently (p = 0.03455) prescribed immunosuppressive therapy, suggesting a more severe rheumatic disease. A not negligible percentage of rheumatic patients in Italy are at potential risk of HBV reactivation related to immunosuppressive therapy. Before starting treatment, subjects should be tested for HBV markers. Those resulting positive should receive treatment or prophylaxis with Nucleos (t) ides analogue (NUCs) at high barrier of resistance, or pre-emptive therapy, according to the pattern of positive markers. HB vaccination is recommended for those who were never exposed to the virus. MDPI 2020-11-16 /pmc/articles/PMC7696870/ /pubmed/33207663 http://dx.doi.org/10.3390/microorganisms8111792 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Canzoni, Marco
Marignani, Massimo
Sorgi, Maria Laura
Begini, Paola
Biondo, Michela Ileen
Caporuscio, Sara
Colonna, Vincenzo
Casa, Francesca Della
Conigliaro, Paola
Marrese, Cinzia
Celletti, Eleonora
Modesto, Irene
Peragallo, Mario Stefano
Laganà, Bruno
Picchianti-Diamanti, Andrea
Rosa, Roberta Di
Ferlito, Claudia
Salemi, Simonetta
D’Amelio, Raffaele
Stroffolini, Tommaso
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title_full Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title_fullStr Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title_full_unstemmed Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title_short Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
title_sort prevalence of hepatitis b virus markers in patients with autoimmune inflammatory rheumatic diseases in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696870/
https://www.ncbi.nlm.nih.gov/pubmed/33207663
http://dx.doi.org/10.3390/microorganisms8111792
work_keys_str_mv AT canzonimarco prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT marignanimassimo prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT sorgimarialaura prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT beginipaola prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT biondomichelaileen prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT caporusciosara prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT colonnavincenzo prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT casafrancescadella prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT conigliaropaola prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT marresecinzia prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT cellettieleonora prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT modestoirene prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT peragallomariostefano prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT laganabruno prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT picchiantidiamantiandrea prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT rosarobertadi prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT ferlitoclaudia prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT salemisimonetta prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT damelioraffaele prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly
AT stroffolinitommaso prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly